Skip to main content

Amgen - Fundamentalanalyse - Jahresbericht / Bilanz / Geschäftsbericht

Amgen (ISIN: US0311621009, WKN: 867900) Kursdatum: 21.07.2017 Kurs: 180,210 USD
Beschreibung Daten
Symbol AMGN
Marktkapitalisierung 135.878.336.512,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ 100NASDAQ Comp.S&P 500
Sektor Pharma
Rohdaten nach US GAAP in Millionen USD
Aktiensplits 1999-11-22 - 2:1 | 1999-03-01 - 2:1 |
Internet
Letztes Bilanz Update 14.02.2017

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 21.07.2017
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
14,28 13,12 2,22% 9,95 38,49 17,60 5,91 4,55

Firmenbeschreibung

Quarterly financial data (unaudited) 2016 Quarters ended(In millions, except per share data)December 31 September 30 June 30 March 31Product sales$5,663 $5,516 $5,474 $5,239Gross profit from product sales$4,596 $4,489 $4,424 $4,221Net income$1,935 $2,017 $1,870 $1,900Earnings per share:       Basic$2.61 $2.70 $2.49 $2.52Diluted$2.59 $2.68 $2.47 $2.50 2015 Quarters ended(In millions, except per share data)December 31 September 30 June 30 March 31Product sales$5,329 $5,516 $5,225 $4,874Gross profit from product sales$4,258 $4,482 $4,136 $3,841Net income$1,800 $1,863 $1,653 $1,623Earnings per share:       Basic$2.39 $2.46 $2.18 $2.13Diluted$2.37 $2.44 $2.15 $2.11

Firmenstrategie

Principles of consolidationThe consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.

RevenueRecognitionPolicyTextBlock

SegmentReportingDisclosureTextBlock

Segment information

We operate in one business segment—human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Enterprise-wide disclosures about product sales; revenues and long-lived assets by geographic area; and revenues from major customers are presented below.

Revenues

Revenues were as follows (in millions):

 
Years ended December 31,
 
2016
 
2015
 
2014
Product sales:
 
 
 
 
 
ENBREL
$
5,965

 
$
5,364

 
$
4,688

Neulasta® 
4,648

 
4,715

 
4,596

Aranesp® 
2,093

 
1,951

 
1,930

Prolia® 
1,635

 
1,312

 
1,030

Sensipar®/Mimpara®
1,582

 
1,415

 
1,158

XGEVA® 
1,529

 
1,405

 
1,221

EPOGEN® 
1,282

 
1,856

 
2,031

NEUPOGEN® 
765

 
1,049

 
1,159

KYPROLIS® 
692

 
512

 
331

Vectibix® 
611

 
549

 
505

Nplate® 
584

 
525

 
469

Repatha® 
141

 
10

 

BLINCYTO® 
115

 
77

 
3

Other
250

 
204

 
206

Total product sales
21,892

 
20,944

 
19,327

Other revenues
1,099

 
718

 
736

Total revenues
$
22,991

 
$
21,662

 
$
20,063


Geographic information

Outside the United States, we sell products principally in Europe. The geographic classification of product sales was based on the location of the customer. The geographic classification of all other revenues was based on the domicile of the entity from which the revenues were earned.

Certain geographic information with respect to revenues and long-lived assets (consisting of property, plant and equipment, net) was as follows (in millions):

 
Years ended December 31,
 
2016
 
2015
 
2014
Revenues:
 
 
 
 
 
United States
$
18,326

 
$
17,167

 
$
15,396

Rest of the world (ROW)
4,665

 
4,495

 
4,667

Total revenues
$
22,991

 
$
21,662

 
$
20,063

EarningsPerSharePolicyTextBlock

Earnings per share

The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which include primarily shares that may be issued under our stock option, restricted stock and performance unit award programs, as determined using the treasury stock method (collectively, dilutive securities).

The computation for basic and diluted EPS was as follows (in millions, except per share data):

 
December 31,
 
2016
 
2015
Long-lived assets:
 
 
 
United States
$
2,328

 
$
 
Years ended December 31,
 
2016
 
2015
 
2014
Income (Numerator):
 
 
 
 
 
Net income for basic and diluted EPS
$
7,722

 
$
6,939

 
$
5,158

 
 
 
 
 
 
Shares (Denominator):
 
 
 
 
 
Weighted-average shares for basic EPS
748

 
758

 
759

Effect of dilutive securities
6

 
8

 
11

Weighted-average shares for diluted EPS
754

 
766

 
770

 
 
 
 
 
 
Basic EPS
$
10.32

 
$
9.15

 
$
6.80

Diluted EPS
$
10.24

 
$
9.06

 
$
6.70


For each of the three years ended December 31, 2016, the number of anti-dilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.